Incidence of chemotherapy-induced nausea and vomiting in Taiwan: Physicians' and nurses' estimation vs. patients' reported outcomes

Supportive Care in Cancer

Volumn 13, Issue 5, 2005, Pages 277-286

  Liau, Chi Ting ^a   Chu, Nei Min ^b   Liu, Hsueh Erh ^c   Deuson, Robert ^d   Lien, Jade ^e   Chen, Jen Shi ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Merck Sharp and Dohme Corp   (Taiwan)

Author keywords

Antiemetic; Chemotherapy; Delayed; Emetogenic; Incidence; Perception

Indexed keywords

ALTRETAMINE; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; LORAZEPAM; METHOTREXATE; METOCLOPRAMIDE; MITOMYCIN; MITOXANTRONE; NAVELBINE; ONDANSETRON; PACLITAXEL; PROCARBAZINE; SEROTONIN ANTAGONIST; TROPISETRON; VINBLASTINE; VINCRISTINE;

ACCURACY; ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ARTICLE; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PRACTICE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; FEMALE; GENERAL PRACTITIONER; HEAD AND NECK CANCER; HUMAN; INCIDENCE; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL PROFESSION; MEDICAL RECORD; MEDICAL SPECIALIST; NASOPHARYNX CANCER; NAUSEA; NURSE; OUTCOMES RESEARCH; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RESIDENCY EDUCATION; STATISTICAL SIGNIFICANCE; TAIWAN; VISUAL ANALOG SCALE;

ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; NURSES; PATIENTS; PHYSICIANS; PROSPECTIVE STUDIES; TAIWAN; VOMITING;

EID: 18744396372     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-005-0788-5     Document Type: Article

References (30)

1. Berger AM, Clark-Snow RA (1997) Adverse effects of treatment, nausea and vomiting. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott-Raven, Philadelphia, pp 2705-2714
2. Hesketh PJ (2000) Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 18:163-173
3. Rhodes VA, Watson PM, Johnson MH, Madsen RW, Beck NC (1987) Patterns of nausea, vomiting, and distress in patients receiving antineoplastic drug protocols. Oncol Nurs Forum 14:35-44
4. Rhodes VA, McDaniel RW (2001) Nausea, vomiting, and retching: complex problems in palliative care. CA Cancer J Clin 51:232-248; quiz 249-252
5. Morrow GR (1989) Chemotherapy-related nausea and vomiting: etiology and management. CA Cancer J Clin 39:89-104
6. Tonato M, Roila F, Del Favero A (1991) Methodology of antiemetic trials: a review. Ann Oncol 2:107-114
7. Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis. Cancer 64:1117-1122
8. Pater J, Slamet L, Zee B, Osoba D, Warr D, Rusthoven J (1994) Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Support Care Cancer 2:161-166
9. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109
10. Yalcin S, Tekuzman G, Baltali E, Ozisik Y, Barista I (1999) Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study. Am J Clin Oncol 22:94-96
11. Roila F, Boschetti E, Tonato M, Basurto C, Bracarda S, Picciafuoco M, et al (1991) Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone: a randomized single-blind study. Am J Clin Oncol 14:238-242
12. Italian Group For Antiemetic Research (1992) Ondansetron+dexamethasone vs metoclopramide+dexamethasone +diphenhydramine in prevention of cisplatin-induced emesis. Lancet 340:96-99
13. Roila F (1993) Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination. Oncology 50:163-167
14. Hesketh PJ, Gandara DR (1991) Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 83:613-620
15. Kris MG, Gralla RJ, Clark RA, Tyson LB (1989) Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst 81:42-46
16. Grunberg SM, Hansen M, Deuson R, Mavros P (2002) Incidence and impact of nausea/vomiting with modern antiemetics: perception vs. reality. Proc Am Soc Clin Oncol 21:250a
17. Gralla RJ, Osoba D, Kris MG, et al (1999) Recommendations for guidelines for the use of antiemetics: evidence-based clinical practice guidelines. J Clin Oncol 17:2971-2994
18. Borjeson S, Hursti TJ, Peterson C, et al (1997) Similarities and differences in assessing nausea and vomiting on a verbal category scale and a visual analogue scale. Cancer Nurs 20:260-266
19. Martin AR, Cai B, Pearson J, et al (2001) Patient-assessed impact of chemotherapy-induced nausea on daily life: how much is too much? Oncol Nurs Forum 28:338
20. Fetting JH, Grochow LB, Folstein MF, Ettinger DS, Colvin M (1982) The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 66:1487-1493
21. Morrow GR (1992) A patient report measure for the quantification of chemotherapy induced nausea and emesis: psychometric properties of the Morrow Assessment of Nausea and Emesis (MANE). Br J Cancer [Suppl] 19:S72-S74
22. Willan A, Warr D, Pater J, et al (1991) Methodological issues and antiemetic studies. In: Osoba D (ed) Effect of cancer on quality of life. CRC Press, Boca Raton, pp 229-249
23. Koo WH, Ang PT (1996) Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 7:71-74
24. Ossi M, Anderson E, Freeman A (1996) 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis. Oncology 53 [Suppl 1]:78-85
25. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971-2994
26. Gralla RJ (1994) Antiemetic treatment for cancer chemotherapy: problems and progress. Support Care Cancer 2:275-276
27. Heron JF (1995) Single-agent oral granisetron for the prevention of acute cisplatin-induced emesis: a double-blind, randomized comparison with granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone. Semin Oncol 22 [4 Suppl 10]:24-30
28. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie MG, Eldridge K, Hipple A, et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090-3098
29. Goedhals L, Heron JF, Kleisbauer JP, Pagani O, Sessa C (1998) Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. Ann Oncol 9:661-666
30. Schnell FM (2003) Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 8:187-198